FDA clears new Physio-Control Lifepak

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Physio-Control, a wholly owned subsidiary of Medtronic, has received clearance from the FDA to market its Lifepak 15 monitor/defibrillator within the U.S.

The new system shares the user interface and footprint of the LIFEPAK 12 defibrillator/ monitor to reduce training and switching costs, the company said.

Additionally, the device includes:

  1. The CPR Metronome with audible prompts has been proven to aid users in performing compressions and ventilations within the recommended range of AHA Guidelines1;
  2. Energy dosing to 360J for difficult-to-defibrillate patients; and
  3. Easy to acquire pre-medication 12-lead ECG and reliable, continuous monitoring of all 12 leads in the background to alert you to changes via our ST Trending feature.

The automated external defibrillator Lifepak 15 monitor will define a "new standard for emergency care products," according to Brian Webster, president of the Redmond, Wash.-based Physio-Control.